US-Based, Credentialed Pharmacies: Ask where the medication is coming from
Takeda, which reported positive data from two pivotal Phase III trials involving zasocitinib last month (NCT06088043 and NCT06108544), bought the drug from Nimbus in 2022 for up to $6 billionincluding $4 billion upfront.
Sample sizes were 6-14 subjects
By reducing AHI, improving your sleep quality, and lowering body mass, GLP-1s may: Restore energy levels Promote a more positive mood Clear brain fog Boost productivity Having more energy makes it a whole lot easier to stay motivated throughout your health journey, empowering you to make lifestyle changes, engage in physical activity, and follow a healthy diet
It contains two long-acting peptide analogues: cagrilintide, a synthetic amylin receptor agonist, and semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist